Lenacapavir, Gilead Sciences' twice-a-year shot, showed almost 100% effectiveness at preventing HIV infection in trials. The clinical story is close to a miracle moment in a four-decade HIV fight. The operational story is a messier reality: getting it into arms, especially across parts of Latin America, is the “biggest test” because the price and supply math does not cooperate.

In Brazil, the impasse has been loud enough to spill onto the stage at the opening ceremony of the International AIDS Society Conference in Rio de Janeiro this week. Activists waved posters and chanted protests that included “Pharma greed is killing us!” and “Pills cost lives!” Dr. Alexandre Padilha, Brazil's health minister, said negotiations with Gilead stalled after the pharma company wanted a price 10 times higher than what Indonesia and Thailand pay. Brazil is stuck in that awkward middle income trap: its status blocks it from the reduced price applied to lower-income countries, yet it still cannot pay the US price.

The numbers behind that trap are stark. In the United States, lenacapavir costs $14,000 a dose, according to the reporting. Gilead has agreed to license generic versions of a pre-exposure prophylaxis (PrEP) medication at around $40 a dose in 120 low- and middle-income countries, but the article says many Latin American countries are being quoted a higher price. Brazil, Mexico, Argentina, and Peru are named among countries with serious HIV epidemics that “do not qualify for the reduced price,” despite having run some of the clinical trials that proved the drug works.

Why does this happen? The core tension is not just ethics, it is incentives. The article describes Brazil’s situation as particularly difficult because it has a law obliging the state to provide treatment, no matter the cost, if it's needed. Draurio Barreira, head of AIDS and TB at Brazil's health ministry, told The Telegraph that this constitutional guarantee may be working against price negotiations. His view, as stated to the outlet, was that manufacturers calculate Brazil cannot walk away from a deal and price accordingly. A Gilead spokesperson pushed back on that characterization, saying Gilead follows regulatory, pricing, and reimbursement processes established within Brazil’s healthcare system and is working collaboratively with governments, communities, and regional partners.

This is where the “breakthrough” becomes a board-level risk and a procurement headache. The article notes that frustration over the speed of lenacapavir rollout has dominated the Rio conference, and could damage Gilead's reputation. That is not a small reputational footnote in pharma, because delays and perceived access gaps can shape how governments, payers, and partners decide whether to prioritize a manufacturer’s next launches. Meanwhile, Gilead argues it is negotiating directly with regional governments and already covers 24 countries in the region. It told The Telegraph it was prioritizing countries with the “greatest HIV burden and even more limited financing capacity.”

But price is only half the constraint. The other half is supply, and it’s structural. Lenacapavir’s twice-yearly form was only first licensed in 2025, and the article says manufacturing capacity is still building. Even in countries covered by Gilead's discounted license, doses remain scarce, with fewer than 250,000 people across the developing world accessing the product. That scarcity matters because, even if a drug is near-100% effective, under-distribution turns prevention into an uneven patchwork rather than a wave.

The access numbers are sobering in Brazil, too. The article says Brazil is home to roughly 1 million people living with HIV, nearly 45% of all HIV cases in Latin America. Yet it has just 6,000 people on long-acting PrEP out of 233,000 total PrEP users nationally, with most people still reliant on daily pills. And UNAIDS data cited in the article says Latin America is one of the few regions where the HIV epidemic is moving the wrong direction: new infections have climbed 25% since 2010, even as Sub-Saharan Africa cut infections by 62% over the same period. UNAIDS Executive Director Winnie Byanyima wants scaling up to 20 million within three years and argues it is within reach, noting the world vaccinated 4.5 billion people against COVID-19 in a single year. She asked Gilead to help “change this.”

For executives watching similar access battles, the strategic twist is that pharma competition may force the market to move. The article points to “innovation in the same category of long-lasting PrEP drugs” from other companies, which might push prices down. It also highlights alternative paths in Brazil that aim to reduce dependency on one supplier. On Tuesday, Fiocruz, Latin America’s largest biomedical research and public health institution tied to Brazil’s ministry of health, signed a memorandum of understanding with MSD Brasil, Merck’s local arm, to explore manufacturing alimatravir, a once-monthly oral pill in Phase 3 trials. Also, Brazil would incorporate ViiV healthcare's long-acting cabotegravir, an injected HIV prevention drug given every two months, into its PrEP program through SUS by the end of the year, after the company offered an “acceptable price” and the drug would still require final agreement and review by Conitec, the advisory body for the country’s health system.

Long-acting PrEP products, the article says, offer the single biggest opportunity to control a virus that has evaded a vaccine for decades. They are easier to administer and track, and they remove stigma tied to daily pills for people at high risk. That is why the rollout fight is bigger than lenacapavir. It is about whether governments can execute prevention at scale with the right regulatory approvals, procurement mechanisms, and implementation readiness, before public health gaps compound.

So the real question for decision-makers is not whether lenacapavir works. Trials say it almost does what everyone has wanted for years. The question is whether health systems, regulators, and suppliers can align money, supply, and timing well enough to convert a clinical result into population impact.